Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 11, 2008
- Isentress Key Drug in HIV Treatment: Banyu
August 11, 2008
- Tokushukai Committed to Settling Prices by End of September
August 11, 2008
- R&D NEWS IN BRIEF
August 11, 2008
- MSNW Supports Rational Drug Pricing
August 11, 2008
- GENERICS NEWS IN BRIEF
August 11, 2008
- JPMA Members Improving Distribution Business Practices: Mr Negi
August 11, 2008
- JRCS Considers Joint Purchase of Generics
August 11, 2008
- Price Settlement Rate Remains at 18% as of June 30: NPhA
August 11, 2008
- Gov't Plans to Create 20 "Super Tokku"
August 11, 2008
- Avapro Holds Top Position 2 Months in a Row: Rep Track Survey
August 11, 2008
- More Research Centers in China
August 11, 2008
- Matsumotokiyoshi Acquires Mogi Pharmaceutical
August 11, 2008
- 9 Asian Studies Started in 2007
August 11, 2008
- Suzuken to Acquire a Dispensing Pharmacy Chain
August 11, 2008
- siRNA Therapeutic to Enter PI in 2009: GeneCare
August 11, 2008
- GSK's New Business Strategy Puts Emphasis on Japanese Market
August 11, 2008
- Amgen Shows Inhibition of Fractures by Denosumab
August 11, 2008
- MTPC Licenses Drug for Hyperparathyroidism from Cytochroma of Canada
August 11, 2008
- Nippon Chemiphar Expects 34.3% Growth Rate for Generics
August 11, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…